Patent · US Active

RSV RNA vaccines

US11911453B2 · kind B2 · utility

18Cited by

58References

13Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Giuseppe Ciaramella · Sudbury, US
Kapil Bahl · Medford, US
Amy Espeseth · Forest Park, US
Andrew J. Bett · Lansdale, US
Pedro Cejas · Oreland, US
Lan Zhang · Forest Park, US
Christine J. Shaw · San Diego, US

Key dates

Filing date	Jan 28, 2019
Grant date	Feb 27, 2024
Priority date	—
Expiry date	Oct 6, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.